Evidence map›Paper›PMID 37759261›Full record

ArticleMicrobial cell factories2023

Cytotoxic effects of halophilic archaea metabolites on ovarian cancer cell lines.

Magdalena Kowalewicz-Kulbat, Krzysztof T Krawczyk, Izabela Szulc-Kielbik, Sebastian Rykowski, Marta Denel-Bobrowska, Agnieszka B Olejniczak, Camille Locht, Magdalena Klink

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Magdalena Kowalewicz-KulbatDepartment of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland. magdalena.kowalewicz@biol.uni.lodz.pl.
Krzysztof T KrawczykDepartment of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Izabela Szulc-KielbikInstitute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
Sebastian RykowskiInstitute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
Marta Denel-BobrowskaInstitute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
Agnieszka B OlejniczakInstitute of Medical Biology, Polish Academy of Sciences, Lodz, Poland.
Camille LochtDepartment of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Magdalena KlinkInstitute of Medical Biology, Polish Academy of Sciences, Lodz, Poland. mklink@cbm.pan.pl.
Institute for Medical Biology · PLUniversity of Łódź · PLCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is one of the most frequent and deadly gynaecological cancers, often resistant to platinum-based chemotherapy, the current standard of care. Halophilic microorganisms have been shown to produce a large variety of metabolites, some of which show toxicity to various cancer cell lines. However, none have yet been shown to be active against ovarian cancer cells. Here, we examined the effects of metabolites secreted by the halophilic archaea Halorhabdus rudnickae and Natrinema salaciae on various cancer cell lines, including ovarian cancer cell lines.

results

conclusionsThe halophilic archaea Hrd. rudnickae and Nnm. salaciae, isolated from a Polish salt mine and Lake Medee in the Mediterranean Sea, respectively, secrete metabolites that are active against ovarian cancer cells, including those that are resistant to cisplatin. This opens potential new possibilities for the treatment of these frequent and deadly gynaecological cancers.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsCell Line, TumorCisplatinFemaleHeLa CellsHumansAntineoplastic AgentsCisplatinArchaeaCytotoxicityHalophilesOvarian cancer cells

Identifiers

PMID37759261
PMCPMC10537157
OpenAlexW4387115038

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.